Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma

Tiotropium bromide is the only long-acting muscarinic antagonist (LAMA) approved for treatment of patients aged ≥6 years old who have symptoms of uncontrolled asthma. Results from several clinical trials have found that once-daily inhaled tiotropium bromide is safe and efficacious in 6- to 17-year-o...

Descripción completa

Detalles Bibliográficos
Autores principales: Santamaria, Francesca, Ziello, Carla, Lorello, Paola, Bouchè, Cristina, Borrelli, Melissa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343620/
https://www.ncbi.nlm.nih.gov/pubmed/35928684
http://dx.doi.org/10.3389/fped.2022.896865
_version_ 1784761029875466240
author Santamaria, Francesca
Ziello, Carla
Lorello, Paola
Bouchè, Cristina
Borrelli, Melissa
author_facet Santamaria, Francesca
Ziello, Carla
Lorello, Paola
Bouchè, Cristina
Borrelli, Melissa
author_sort Santamaria, Francesca
collection PubMed
description Tiotropium bromide is the only long-acting muscarinic antagonist (LAMA) approved for treatment of patients aged ≥6 years old who have symptoms of uncontrolled asthma. Results from several clinical trials have found that once-daily inhaled tiotropium bromide is safe and efficacious in 6- to 17-year-olds with symptomatic asthma despite treatment with inhaled corticosteroids, with or without other medications. There are still few available studies investigating the impact of tiotropium bromide treatment in preschool children with suboptimal control. In this narrative review, we summarize the pharmacological effects of the LAMA tiotropium bromide, provide an overview about current asthma studies at different pediatric ages, and describe future research needs.
format Online
Article
Text
id pubmed-9343620
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93436202022-08-03 Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma Santamaria, Francesca Ziello, Carla Lorello, Paola Bouchè, Cristina Borrelli, Melissa Front Pediatr Pediatrics Tiotropium bromide is the only long-acting muscarinic antagonist (LAMA) approved for treatment of patients aged ≥6 years old who have symptoms of uncontrolled asthma. Results from several clinical trials have found that once-daily inhaled tiotropium bromide is safe and efficacious in 6- to 17-year-olds with symptomatic asthma despite treatment with inhaled corticosteroids, with or without other medications. There are still few available studies investigating the impact of tiotropium bromide treatment in preschool children with suboptimal control. In this narrative review, we summarize the pharmacological effects of the LAMA tiotropium bromide, provide an overview about current asthma studies at different pediatric ages, and describe future research needs. Frontiers Media S.A. 2022-07-19 /pmc/articles/PMC9343620/ /pubmed/35928684 http://dx.doi.org/10.3389/fped.2022.896865 Text en Copyright © 2022 Santamaria, Ziello, Lorello, Bouchè and Borrelli. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pediatrics
Santamaria, Francesca
Ziello, Carla
Lorello, Paola
Bouchè, Cristina
Borrelli, Melissa
Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma
title Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma
title_full Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma
title_fullStr Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma
title_full_unstemmed Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma
title_short Update on Long-Acting Anticholinergics in Children and Adolescents With Difficult and Severe Asthma
title_sort update on long-acting anticholinergics in children and adolescents with difficult and severe asthma
topic Pediatrics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343620/
https://www.ncbi.nlm.nih.gov/pubmed/35928684
http://dx.doi.org/10.3389/fped.2022.896865
work_keys_str_mv AT santamariafrancesca updateonlongactinganticholinergicsinchildrenandadolescentswithdifficultandsevereasthma
AT ziellocarla updateonlongactinganticholinergicsinchildrenandadolescentswithdifficultandsevereasthma
AT lorellopaola updateonlongactinganticholinergicsinchildrenandadolescentswithdifficultandsevereasthma
AT bouchecristina updateonlongactinganticholinergicsinchildrenandadolescentswithdifficultandsevereasthma
AT borrellimelissa updateonlongactinganticholinergicsinchildrenandadolescentswithdifficultandsevereasthma

Ejemplares similares